A range of ICAM1 ADCs were generated with different linkers and payloads including an ADC with non-cleavable linker and low cell permeable drug (ICAM1-DM1), which showed the greatest potency against pancreatic cancer cells while not altering the viability of normal human pancreatic duct epithelial cells. Here, ICAM1 is linked to pancreatic neoplasm.